CervoMed Inc. (CRVO), a clinical-stage biotechnology company, on Tuesday reported that its drug candidate Neflamapimod has received an Innovation Passport to enter the UK's Innovative Licensing and Access Pathway (ILAP) for development in treating Dementia with Lewy Bodies.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.